Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Compston
J E
JE
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000494:pharmacology; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*
D002120:Calcium Channel Agonists; D002121:Calcium Channel Blockers; D004965:Estrogen Antagonists; D020849:Raloxifene Hydrochloride; D002117:Calcitriol; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate